Vitiligo
Conditions
Interventions
Treatment group:Hydroxychloroquine combined with topical halometasone/triclosan cream
Sponsors
Dermatology Hospital of Southern Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Diagnostic criteria of progressive nonsegmental vitiligo, VIDA score >= 1; 2. Patients with moderate to severe nonsegmental vitiligo involving the face and neck were selected, with leukoplakia area >= 5%, or facial leukoplakia area >= 1%; 3. Patients with poor efficacy of routine treatments such as oral glucocorticoids or phototherapy given systematically; 4. Informed and agreed to participate in this study; 5. Patients aged 18 to 65 years, regardless of gender.
Exclusion criteria
Exclusion criteria: 1. Systematic use of glucocorticoids, immunosuppressive therapy, or phototherapy, topical use of glucocorticoids/immunomodulators within 1 month; 2. Those who spontaneously recolor; 3. Women who are pregnant, breastfeeding, or have a childbirth plan in the past six months; women of childbearing age have a positive pregnancy test; 4. People with mental abnormalities merged; 5. Patients with retinal lesions or serious diseases, such as serious heart, brain, liver, kidney and other system diseases, or malignant tumors; 6. Any one of the following abnormalities in laboratory test results during screening: peripheral blood white blood cell count 15 x 10^9/L, lymphocytes 1.5 x ULN; serum creatinine, BUN > 1.5 x ULN; triglycerides or total cholesterol > 1.5 x ULN; 7. A history of human immunodeficiency virus (HIV) or HIV seropositivity during screening. There is evidence that mycobacterium tuberculosis (TB) is active, latent or inadequately treated; 8. Those who have participated in other clinical trials in the past 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Vitiligo area; | — |
Secondary
| Measure | Time frame |
|---|---|
| VASI(vitiligo area scoring index) 75 of face;VASI100;VASI50;VitiQoL (the vitiligo-specific quality-of-life instrument); | — |
Countries
China
Contacts
Public ContactLuo Guangpu
Dermatology Hospital of Southern Medical University
Outcome results
None listed